129 related articles for article (PubMed ID: 26049547)
1. In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.
Vanderstraeten A; Everaert T; Van Bree R; Verbist G; Luyten C; Amant F; Tuyaerts S
J Immunother; 2015; 38(6):239-49. PubMed ID: 26049547
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.
Vanderstraeten A; Tuyaerts S; Everaert T; Van Bree R; Verbist G; Luyten C; Amant F
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618037
[TBL] [Abstract][Full Text] [Related]
3. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
4. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
5. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
[TBL] [Abstract][Full Text] [Related]
6. Survivin--a universal tumor antigen.
Andersen MH; thor SP
Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
[TBL] [Abstract][Full Text] [Related]
7. The universal character of the tumor-associated antigen survivin.
Andersen MH; Svane IM; Becker JC; Straten PT
Clin Cancer Res; 2007 Oct; 13(20):5991-4. PubMed ID: 17947459
[TBL] [Abstract][Full Text] [Related]
8. High expression of survivin and its splice variants survivin ΔEx3 and survivin 2 B in oral cancers.
Mishra R; Palve V; Kannan S; Pawar S; Teni T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Oct; 120(4):497-507. PubMed ID: 26346910
[TBL] [Abstract][Full Text] [Related]
9. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
10. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
Ayyoub M; Taub RN; Keohan ML; Hesdorffer M; Metthez G; Memeo L; Mansukhani M; Hibshoosh H; Hesdorffer CS; Valmori D
Cancer Immun; 2004 Aug; 4():7. PubMed ID: 15298487
[TBL] [Abstract][Full Text] [Related]
11. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.
Turksma AW; Bontkes HJ; Ruizendaal JJ; Scholten KB; Akershoek J; Rampersad S; Moesbergen LM; Cillessen SA; Santegoets SJ; de Gruijl TD; Leemans CR; Meijer CJ; Hooijberg E
J Transl Med; 2013 Jun; 11():152. PubMed ID: 23787039
[TBL] [Abstract][Full Text] [Related]
12. A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis.
Sørensen RB; Svane IM; Straten PT; Andersen MH
Cancer Biol Ther; 2008 Dec; 7(12):1885-7. PubMed ID: 18927499
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
14. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies.
Friedrichs B; Siegel S; Andersen MH; Schmitz N; Zeis M
Leuk Lymphoma; 2006 Jun; 47(6):978-85. PubMed ID: 16840186
[TBL] [Abstract][Full Text] [Related]
15. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide.
Gang Y; Zhang X; He Y; Zheng J; Wu K; Ding J; Fan D
Biochem Cell Biol; 2012 Dec; 90(6):701-8. PubMed ID: 22992138
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy in soft tissue sarcoma.
Indelicato DJ; Finkelstein SE
Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
[TBL] [Abstract][Full Text] [Related]
17. T-cell target antigens across major gynecologic cancers.
Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
[TBL] [Abstract][Full Text] [Related]
20. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
